Kane Biotech Cash Flow | StatInvestor

Health Care & Life Sciences » Biotechnology | Kane Biotech Inc.

Kane Biotech Inc. | Cash Flow

Fiscal year is January-December. All values CAD Thousands.

2013

2014

2015

2016

2017

2018

Net Income before Extraordinaries

1,447.40

1,614.90

1,710.00

2,548.70

2,786.20

3,261

Depreciation, Depletion & Amortization

35.40

39.20

42.60

49.00

69.40

71.80

Other Funds

336.40

437.00

276.70

204.70

245.90

382.40

Funds from Operations

1,075.50

1,138.60

1,390.80

2,295.00

2,470.80

2,806.80

Changes in Working Capital

90.90

89.50

2.30

68.30

426.60

47.20

Net Operating Cash Flow

1,166.40

1,049.20

1,388.50

2,363.30

2,044.20

2,854

Capital Expenditures

133.40

186.80

109.50

266.00

229.60

Net Investing Cash Flow

133.40

186.80

109.50

266.00

229.60

Issuance/Reduction of Debt, Net

481.80

17.50

9.50

514.80

Net Financing Cash Flow

519.30

1,567.70

648.10

3,252.60

3,510.00

Net Change in Cash

780.60

331.70

849.90

623.30

1,236.20

Free Cash Flow

1,176.70

1,055.30

1,399.60

2,400.40

2,057.50

Change in Capital Stock

37.50

1,585.20

657.70

3,252.60

4,024.80

About Kane Biotech

View Profile

Address	196 Innovation Drive Winnipeg Manitoba R3T 2N2 Canada
Employees	-
Website	http://www.kanebiotech.com
Updated	07/08/2019
Kane Biotech, Inc. is a biotechnology company, which engages in the development and commercialization of products to prevent and remove biofilms. It uses a patent protected technology based on molecular mechanisms of biofilm formation and methods for finding compounds that inhibit or disrupt biofilms. Its trademarks include StrixNB, DispersinB, Aledex, blueste, AloSer, coactive, and Kane.